Oral Formulations Of Deferasirox

Patent No. EP2964202 (titled "Oral Formulations Of Deferasirox") was filed by Novartis on Mar 6, 2014. The application was issued on May 31, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
INVOKAT SERVICESJul 31, 2019MUTLU
HGFJul 30, 2019HGF
TEVA PHARMACEUTICALSJul 23, 2019ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2964202

NOVARTIS
Application Number
EP14710654A
Filing Date
Mar 6, 2014
Status
Patent Maintained As Amended
Apr 28, 2023
Publication Date
May 31, 2023